SINGLE-AF: DOAC Therapy vs. No Anticoagulation in AFib Patients at Intermediate Risk For Stroke
Clinical trial data from ESC 2026 reveals oral anticoagulants reduce stroke risk in intermediate-risk atrial fibrillation patients.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Outcome review added Archynetys revisited the signal after coverage cooled.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 9.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
Source diversity sample: Korea Biomedical Review · Medscape · en.sedaily.com · News-Medical · HCPLive · Medical Xpress · TCTMD.com · MedPage Today.
How this dossier is built: methodology · AI policy · corrections.
Where it stands
New clinical trial data presented at ESC 2026 addresses the use of direct oral anticoagulants in atrial fibrillation patients at intermediate risk for stroke. The SINGLE-AF study provides findings on DOAC therapy versus no anticoagulation in this specific patient population.
Simultaneously, separate findings regarding edoxaban in atrial fibrillation patients after intracranial hemorrhage indicate that new evidence does not support its use in that context, with coverage from sources like ENRICH-AF noting increased bleeding without a reduction in stroke. Despite the contrasting outcomes in post-hemorrhage patients, multiple outlets including Medscape, TCTMD, MedPage Today, and the American College of Cardiology report that the SINGLE-AF trial marks a major trial win for contemporary DOACs in lower-risk afib by demonstrating reduced stroke risk.
Coverage does not yet specify subsequent regulatory or clinical guideline updates following these presentations from the ESC 2026 meetings.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 5h ago.
Sources (12)
- [ESC 2026] SINGLE-AF study closes evidence gap on DOACs in intermediate-risk AF Korea Biomedical Review · 6d ago
- To Anticoagulate or Not in Intermediate-Risk AF: The SINGLE-AF Trial Medscape · 6d ago
- Blood Thinners Cut Stroke Risk in Moderate-Risk Heart Patients en.sedaily.com · 7d ago
- New findings do not support the use of edoxaban in AF patients after intracranial hemorrhage News-Medical · 7d ago
- ENRICH-AF: Edoxaban Increases Bleeding Without Reducing Stroke HCPLive · 7d ago
- People with atrial fibrillation at intermediate risk of stroke benefit from oral anticoagulants, clinical trial finds Medical Xpress · 7d ago
- DOACs Benefit AF Patients With Intermediate Stroke Risk: SINGLE-AF TCTMD.com · 7d ago
- First Major Trial Win for Contemporary DOACs in Lower-Risk Afib MedPage Today · 7d ago
- SINGLE-AF: Oral Anticoagulants Reduce Risk of Stroke in Patients With AF HCPLive · 7d ago
- Oral anticoagulants benefit patients with atrial fibrillation at intermediate stroke risk News-Medical · 7d ago
- DOACs Benefit AF Patients With Intermediate Stroke Risk Medscape · 7d ago
- SINGLE-AF: DOAC Therapy vs. No Anticoagulation in AFib Patients at Intermediate Risk For Stroke American College of Cardiology · 7d ago
Answered
What does the SINGLE-AF study examine?
The SINGLE-AF study compares direct oral anticoagulant therapy versus no anticoagulation in atrial fibrillation patients who are at intermediate risk for stroke.
What were the findings regarding edoxaban after intracranial hemorrhage?
Findings indicate that edoxaban increases bleeding without reducing stroke in atrial fibrillation patients after intracranial hemorrhage.
Which outlets covered the SINGLE-AF trial results?
Coverage includes Medscape, TCTMD, MedPage Today, the American College of Cardiology, and Korea Biomedical Review, among others.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
2026 ESC Guidelines for the management of heart failure
ESC’s 2026 heart‑failure guidelines elevate finerenone to top‑tier status, reshaping treatment and diagnosis for clinicians worldwide.
Artificial sweetener linked to higher risk of cardiovascular events
A widely used sweetener found in food, beverages, and gum is now linked to a higher risk of heart attacks and strokes.
Antithrombotic Therapy After TAVI
Recent clinical trials provide mixed messages regarding direct oral anticoagulant therapy following transcatheter aortic valve implantation.
Does AF Ablation Work? That’s in Question After PVI-SHAM-AF
New sham-controlled trial data questions whether atrial fibrillation catheter ablation actually improves patient quality of life.
Exercise intervention associated with reduced atrial fibrillation burden - News-Medical
A new study shows that exercise can significantly reduce the burden of atrial fibrillation, a condition affecting millions worldwide.
Atorvastatin reduces major cardiovascular events but misses disability-free survival goal - News-Medical
A 30% cut in heart attacks for seniors sparks debate over over‑the‑counter statins despite unchanged disability outcomes.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.